International neuroblastoma risk group consortium: a model of networking for rare cancers

Susan L Cohn1, Wendy B London2, Gudrun Schleiermacher3

  • 1Department of Pediatrics, Comer Children's Hospital and University of Chicago, Chicago, IL, United States.

Insights

International collaboration in rare cancer research, exemplified by the International Neuroblastoma Risk Group (INRG), optimizes progress through data sharing and harmonized approaches. This model benefits numerous rare pediatric and adult malignancies.

Area of Science:

  • Oncology
  • Data Science
  • Rare Cancers

Background:

  • Optimizing rare cancer research requires knowledge sharing and harmonized approaches.
  • The International Neuroblastoma Risk Group (INRG) Task Force was established in 2004 by major neuroblastoma cooperative groups.
  • Neuroblastoma strategies serve as a model for other rare malignancies.

Purpose of the Study:

  • To establish a data-sharing model for rare cancers.
  • To harmonize approaches in rare cancer research.
  • To facilitate international collaboration and accelerate discoveries.

Main Methods:

  • Formation of the INRG Task Force by four major neuroblastoma cooperative groups.
  • Development of the INRG Data Commons, aggregating data from over 25,000 patients.
  • Creation of standardized staging, risk classification, and consensus criteria for biological data and treatment response.

Main Results:

  • The INRG Data Commons provides access to data for over 25,000 patients.
  • INRG staging and risk systems have led to harmonized therapeutic groupings.
  • Over forty INRG research studies have been conducted, including analyses of rare patient subsets.
  • The INRG model has been expanded to sixteen other cancers and conditions.

Conclusions:

  • The INRG's international networking and data-sharing model has driven significant progress in neuroblastoma research.
  • This collaborative framework has been successfully applied to other rare pediatric and adult cancers.
  • The model serves as a blueprint for advancing research in rare malignancies globally.

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.4K